Pazopanib
VOTRIENT®

About VOTRIENT®
-
Marketed by Novartis Pharmaceuticals Corporation (United States and European Union) and GlaxoSmithKline plc (Japan)
-
Selective multi-targeted receptor tyrosine kinase inhibitor
-
Treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma
Review and approval status
June 14, 2010
First E.U. approval
October 19, 2009
First U.S. approval
Actual and expected launch:
- 2023: Patent expiry: United States
- 2025: SPC expiries: European Union
- 2027: Patent expiry: Japan
Patents estimated to expire beginning in 2039
API availability

